Allergan successfully completes Kythera acquisition
KYBELLA® first FDA-approved non-surgical injection for submental fullness bolsters Allergan’s world-class facial aesthetics portfolio
Read MoreKYBELLA® first FDA-approved non-surgical injection for submental fullness bolsters Allergan’s world-class facial aesthetics portfolio
Read MoreOct 6, 2014 | 0 |
Klaus Hoffmann reviews the results of phase I, II, and III clinical studies using ATX-101 for the reduction of submental fat and discusses its potential use in clinical practice
Read MoreMay 7, 2014 | 0 |
Skin laxity and fat build-up under the chin is a common concern among facial aesthetic patients. Although surgery has long...
Read MoreNov 27, 2013 | 0 |
Topokine Therapeutics has initiated dosing in a Phase 2, randomised controlled clinical trial of XAF5 Gel for reduction of excess...
Read More